慢性骨髄性白血病（CML）とは、骨髄内部の造血細胞が変異して、血液中に侵入していくという癌の一種です。主なリスク要因には、高線量放射線の被爆や年齢・性別などがあります。主な症状として、疲労感や倦怠感、寝汗、体重減少、発熱、骨痛、脾臓の肥大化、下腹部の痛みや膨満感などが挙げられます。主な治療法には、放射線療法や造血細胞移植、化学療法などがあります。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
Featured News & Press Releases
Sep 21, 2022: Ascentage Pharma announces phase I/II data of olverembatinib (HQP1351) published in the Journal of Hematology & Oncology, further validating the drug's best-in-class potential
Aug 31, 2022: Scemblix, a first-in-class CML treatment with new mechanism of action approved in Canada
Aug 29, 2022: Novartis Scemblix, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia
Aug 26, 2022: Inhibikase Therapeutics announces FDA clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Jul 22, 2022: Ascentage Pharma and Tanner Pharma Group initiate a global innovative Named Patient Program
Jul 21, 2022: Ascentage Pharma announces clinical trial application for Olverembatinib (HQP1351) approved in Canada
Jul 19, 2022: The National Medical Products Adminstration accepted and granted priortiy review designation to a new drug application for olverembatinib for the treatment of drug-resistant chornic myeloid leukemia
Jun 30, 2022: First STAMP (specifically targeting the abl myristoyl pocket) inhibitor for treatment for chronic myeloid leukaemia (CML), Scemblix (asciminib) receives NICE final draft recommendation in Great Britain
Jun 24, 2022: Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia
Jun 07, 2022: Novartis Scemblix, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
Jan 05, 2022: The first commercial insurance landed in Huzhou, and Ascentage Pharma's Nerike was included in the "Zheli Medical Insurance South Taihu Health Insurance"
Dec 14, 2021: ASH 2021 | Ascentage Pharma releases long-term clinical data of olverembatinib (HQP1351) in oral presentation demonstrating efficacy and safety
Dec 11, 2021: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
Nov 25, 2021: Ascentage Pharma announces approval by NMPA for China's first approved third-generation BCR-ABL TKI HQP1351 (Olverembatinib)
Nov 22, 2021: Ascentage Pharma's olverembatinib granted orphan designation by the European Commission for the treatment of chronic myeloid leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, 2022
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, 2022
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, 2022 (Contd..1)
List of Figures
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
